Curated News
By: NewsRamp Editorial Staff
August 24, 2026
Scinai Immunotherapeutics Reports Revenue Growth and Advances CDMO Program
TLDR
- Scinai's CDMO revenue grew 23% to $949K, with $3.1M in orders, signaling strong momentum for investors.
- Scinai's H1 2026 revenue rose to $949K, operating loss widened to $4.6M, but net income swung positive due to a $6.4M bargain purchase gain.
- Scinai advances therapies for immune diseases and supports U.S. drug development, aiming to bring new treatments to patients.
- Scinai acquired Recipharm Israel, boosting capabilities and generating a $6.4M bargain purchase gain, and hosts an investor webinar Aug 26.
Impact - Why it Matters
This news matters because it highlights Scinai's dual strategy of leveraging its CDMO services to generate revenue while advancing its therapeutic pipeline. The expansion of the CMC program for a U.S. biopharmaceutical company indicates growing trust in Scinai's manufacturing capabilities, which could lead to more partnerships and financial stability. For investors, the company's improved net income and revenue growth suggest a positive trajectory, while the upcoming webinar offers an opportunity to gain insights into future milestones. For the biopharmaceutical industry, Scinai's progress underscores the importance of CDMOs in supporting drug development and the potential for smaller companies to thrive by offering specialized services.
Summary
Scinai Immunotherapeutics (NASDAQ: SCNI) has reported a solid financial performance for the first half of 2026, with revenue climbing to $949,000 from $773,000 in the prior-year period. The company, which combines therapeutic development with a contract development and manufacturing organization (CDMO), has seen committed customer orders reach approximately $3.1 million as of August 16, 2026, including about $2.1 million already invoiced. This growth underscores the momentum in its CDMO business, which is pivotal to its strategy of generating revenue while advancing its pipeline.
In a significant development, Scinai is expanding its clinical manufacturing and chemistry, manufacturing and controls (CMC) program for a U.S.-based biopharmaceutical company, having received approximately $650,000 in cash payments and advances. The program is intended to support an investigational drug product toward a U.S. investigational new drug (IND) submission and Phase III clinical development. While a definitive agreement is still under negotiation, substantive activities are already underway, signaling strong client commitment. The company continues to pursue approximately $5 million in CDMO revenue for 2026, reflecting its confidence in sustained growth.
Financially, Scinai reported an operating loss of approximately $4.6 million for the first half, compared to $3.8 million a year earlier, but achieved a net income of approximately $1.6 million versus a net loss of approximately $4.1 million, primarily due to a $6.4 million bargain purchase gain from the acquisition of Recipharm Israel. Cash and cash equivalents stood at approximately $2.9 million as of June 30, 2026. The company continues to advance its PC111 and NanoAbs therapeutic programs and will host an investor webinar on August 26, 2026, to discuss recent developments and upcoming milestones. For more details, visit the full press release at https://nnw.fm/Be7Ky.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Immunotherapeutics Reports Revenue Growth and Advances CDMO Program
